Edwards Lifesciences wins FDA approval for AUTUS pediatric pulmonary valve

By Public Technologies
  • Edwards Lifesciences won FDA clearance for its AUTUS size-adjustable surgical pulmonary valve for pediatric congenital heart disease patients.
  • The device can be expanded later via a transcatheter procedure, aiming to reduce repeat open-heart surgeries as children grow.
  • Approval was supported by a pivotal study showing 100% freedom from device-related complications at 30 days, no reinterventions through six months.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edwards Lifesciences Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 202610011626BIZWIRE_USPR_____20261001_BW568896) on October 01, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk